Seize the initiative! Hangzhou cancer hospital, carried out CRISPR in the treatment of esophageal cancer clinical trials
Hangzhou tumor hospital bed, the 53-year-old construction worker is waiting for your own Doctor. Mr. Deng is one of the esophageal cancer patients, receiving radiotherapy and chemotherapy after the cancer continued to spread.
According to the China National Cancer Center, esophageal cancer is China the most common form of cancer. And other cancers, as, at present, esophageal cancer the standard treatment is still the traditional chemotherapy, but the treatment result is not ideal. In China and around the world, new effective therapies are urgently developed.
Recently, according to media reports: Hangzhou tumor hospital Dean serves as the Hangzhou Institute of Oncology Director, Wu 琇 Director of physicians test a new method of treatment, by the patient’s T cells for gene editing(Anhui Kirton biotechnology Co., Ltd. lab use CRISPR technology to knockout T cells of PD-1 gene), make it target cancer cells, the modified T cells reinfusion into the patient to be able to play anti-cancer effect. Actually from last 3 months onwards, Wu 琇 the doctor will try to use CRISPR-Cas9 technology in the treatment of esophageal cancer patients. And China as the world’s first CRISPR for human trials in the country, so far at least 86 Chinese patients receiving the gene editing treatment.
This time, Deng Mr. in Hangzhou cancer hospital is the pilot treatment programme. He expressed himself very lucky. At the completion of the blood pressure after the test, the nurse will be filled with a pale yellow liquid of a transparent plastic bag hanging on Deng in the hospital bed, the start of the intravenous infusion.
As this study’s main leader, Wu 琇 the doctor said:“this step is a T cell infusion, the patient now has the start of the immune cells of the treatment.” Millions of genetically modified immune cells to slowly drip into the patient’s body, at least an hour.
In accepting the first gene edited T cells after infusion soon, Deng’s condition is improved. Now, he has already received a second treatment. Currently, the accepted treatment of the 21-bit advanced esophageal cancer(other treatment options for these patients to invalid). To date, there have been 40%of the patients on the therapy had a positive response. One of the patients after one year still survive.
According to Wu 琇 doctors, this study has no randomized control group. But usually, the majority of advanced esophageal cancer patient in three to six months to death, if not to accept such treatment, almost no hope for survival. Currently, on this experimental therapy, the Wu formula 琇 the doctor is writing a thesis.
It is worth noting that the Deng participated in this clinical trial is domestic CRISPR human trials and important research. Currently, China has in the global Biomedical Research Centre for the exchange of a United States government website discloses at least eight items on CRISPR in the treatment of various cancer studies. Wherein the indications include lung cancer, bladder cancer, cervical cancer and prostate cancer. And as early as 2016, 7 month, Sichuan West China hospital Ethics Committee approved the lumwana uranium team of clinical trial research, to become the world’s first CRISPR clinical trials.
In contrast, in the United States there is only one CRISPR Cancer Research approved. 2017 1 January, Nature Biotechnology magazine in an article entitled“CRISPR therapeutics push into human testing,”the News reported an item based on the CRISPR of T cells for cancer immunotherapy Phase I clinical trials program of the latest progress. The article said, the trials by the University of Pennsylvania and its partners—the University of California, San Francisco, and MD Anderson Cancer Center are jointly responsible for, the reports clearly stated that Carl June, Professor in a clinical trial of a science adviser.
2018 1 October, according to foreign media reports, the US is about to openStarting for the first time CRISPR human trials, and the fact that in 2016, the US National Institutes of Health(NIH), an Advisory panel has approved the University of Pennsylvania CRISPR human trials. Planned for 2017 the beginning of the summer test and got Parker for cancer immunotherapy, Institute of financing, but the specific start time has not been determined, until recently, the CRISPR gene editing human trials ranked the University of Pennsylvania published clinical trials directory, it indicates that the study is about to begin. By Penn a spokesman confirmed that the clinical test preparations are in the final stages.
The study planned to Recruit 18 myeloma, osteosarcoma and melanoma patients. Specific treatment options include from the patient extraction of T cells, the use of CRISPR gene editing technology to knockout T cells, the two genes, the reprogramming of T cells to better recognize and attack the above three types of cancer cells by genetically modified T cells vein reinfusion into the patient.
In addition, since the gene editing technology application the risk is still there. Therefore, in order to assess relates to the gene therapy research of risks and the investigation of deaths and side effects reports the University of Pennsylvania established the recombinant DNA Research Committee. Above, we can see that: the United States is the reason for the loss of the leading edge is the main reason for its regulation is more stringent, the need through various risk assessment and security check, in as much as possible to ensure patient safety under the premise, to the implementation of gene editing of the clinical trials.
Of course, the same research concerns in China also exists, Wu 琇 the doctor made it clear that in advance to inform patients of treatment risks, many patients are still willing to accept new treatment options. Just as Chinese old saying 好死不如赖活着 it! And this is also the ethics Committee and the laboratory for this very positive cause.
Currently, Wu 琇 doctor also started for other the treatment of cancer patients, especially pancreatic cancer. He said:“although only just begun, but we should be constantly improved with a view to as many cancer patients bring more benefits. And if you do not try, you will never know the result.”
*statement: this article by the settled Sina pharmaceutical news authored, the views are those of the authors themselves, does not mean Sina pharmaceutical News Stand. span>
Published at Thu, 24 Feb 2018 07:03:29 +0000